PROPYLTHIOURACIL
LOE ApproachingNDAORALTABLET
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PROPYLTHIOURACIL by Eli Lilly and Company is clinical pharmacology propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. First approved in 1947.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Propylthiouracil (PTU) is a small-molecule antithyroid agent that inhibits thyroid hormone synthesis and peripheral conversion of thyroxine to triiodothyronine, making it effective for hyperthyroidism and thyroid storm. It is an oral tablet approved since 1947 by Eli Lilly and Company. The drug does not inactivate existing thyroid hormones but prevents new hormone production.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating defensive brand management and transition planning opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood, nor does it interfere with…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on propylthiouracil offers exposure to legacy brand management, healthcare economics, and specialty endocrinology markets. This is an ideal role for professionals focused on operational excellence, regulatory compliance, and managing mature product lifecycles rather than growth-stage innovation.
Regulatory Affairs Specialist
Worked on PROPYLTHIOURACIL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.